{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:07:13Z","timestamp":1777860433839,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.jfo.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T23:23:04Z","timestamp":1557616984000},"page":"612-617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Facteurs pronostiques de l\u2019atteinte oculaire dans la maladie de Beh\u00e7et"],"prefix":"10.1016","volume":"42","author":[{"given":"K.","family":"Belkhadir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Boutimzine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Laghmari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Amazouzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tachfouti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Cherkaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2019.03.009_bib0100","doi-asserted-by":"crossref","unstructured":"Criteria for diagnosis of Beh\u00e7et's disease. International Study Group for Beh\u00e7et's Disease. Lancet 1990; 335:1078-80.","DOI":"10.1016\/0140-6736(90)92643-V"},{"key":"10.1016\/j.jfo.2019.03.009_bib0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The International Criteria for Beh\u00e7et's Disease (ICBD): a collaborative study of 27\u00a0countries on the sensitivity and specificity of the new criteria","volume":"28","author":"International Team for the Revision of the International Criteria for Beh\u00e7et's Disease (ITR-ICBD)","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0110","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.revmed.2018.02.022","article-title":"Ocular manifestations in Beh\u00e7et's disease","volume":"39","author":"Desbois","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jfo.2019.03.009_bib0115","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/acr.20308","article-title":"Azathioprine in severe uveitis of Beh\u00e7et's disease","volume":"62","author":"Saadoun","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jfo.2019.03.009_bib0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880\u00a0patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0125","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","article-title":"Treatment and visual prognosis in Beh\u00e7et's disease","volume":"70","author":"Benezra","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jfo.2012.06.016","article-title":"The eye and Beh\u00e7et's disease","volume":"35","author":"Khairallah","year":"2012","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369\u00a0patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jfo.2019.03.009_bib0140","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10792-013-9788-5","article-title":"Current and future treatments for Beh\u00e7et's uveitis: road to remission","volume":"34","author":"Mesquida","year":"2014","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0145","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/keu266","article-title":"Anti-TNF-\u03b1 therapy in patients with refractory uveitis due to Beh\u00e7et's disease: a 1-year follow-up study of 124\u00a0patients","volume":"53","author":"Calvo-R\u00edo","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.jfo.2019.03.009_bib0150","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jfo.2019.03.009_bib0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08820538.2011.588665","article-title":"The use of biologic agents in the treatment of ocular manifestations of Behcet's disease","volume":"26","author":"Benitah","year":"2011","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0160","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Beh\u00e7et's disease: beyond anti-TNF therapy","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jfo.2019.03.009_bib0165","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018\u00a0update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jfo.2019.03.009_bib0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1\u00a0inhibition with anakinra and canakinumab in Beh\u00e7et's disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0175","first-page":"171","article-title":"Interleukin-1\u00a0Inhibition in Beh\u00e7et's disease","volume":"18","author":"Vitale","year":"2016","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.jfo.2019.03.009_bib0180","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","article-title":"Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review","volume":"45","author":"Deroux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jfo.2019.03.009_bib0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10067-013-2433-x","article-title":"Improved clinical control of a challenging case of Beh\u00e7et's disease with rituximab therapy","volume":"33","author":"Zhao","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jfo.2019.03.009_bib0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3899\/jrheum.130206","article-title":"Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement","volume":"41","author":"Pelegrin","year":"2014","journal-title":"J Rheumatol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219302384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551219302384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:09:22Z","timestamp":1759259362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551219302384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0181551219302384"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2019.03.009","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facteurs pronostiques de l\u2019atteinte oculaire dans la maladie de Beh\u00e7et","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}